Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients

20155 citationsJournal Article

Authors

Amber C. King · The University of Texas MD Anderson Cancer Center

Q. Maggie · The University of Texas MD Anderson Cancer Center

Gary B. Chisholm · The University of Texas MD Anderson Cancer Center

Katy M. Toale · The University of Texas MD Anderson Cancer Center

Abstract

Cancer patients receiving once daily enoxaparin for the treatment of acute PE may be at increased risk of recurrent PE and clinically overt bleeding. Larger randomized trials are needed to confirm the results of this study.

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Case Reports on Hematomas Spinal Hematomas and Complications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Oncology Pharmacy Practice

Volume 22, Issue 2, pp. 265-270

DOI: 10.1177/1078155215583374

Field-Weighted Citation Impact: 0.27